PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

BACKGROUND: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Buckley, Hannah L., Collinson, Fiona J., Ainsworth, Gemma, Poad, Heather, Flanagan, Louise, Katona, Eszter, Howard, Helen C., Murden, Geraldine, Banks, Rosamonde E., Brown, Joanne, Velikova, Galina, Waddell, Tom, Fife, Kate, Nathan, Paul D., Larkin, James, Powles, Thomas, Brown, Sarah R., Vasudev, Naveen S.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854710/
https://ncbi.nlm.nih.gov/pubmed/31727024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6273-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados